Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Antibiotic

Co-amoxiclav

Brand names: Augmentin

Co-amoxiclav combines amoxicillin with the beta-lactamase inhibitor clavulanic acid, used in obstetrics and gynaecology for polymicrobial infections such as severe pelvic infection, chorioamnionitis and post-surgical infection.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Amoxicillin inhibits bacterial cell-wall synthesis while clavulanic acid protects it from beta-lactamase enzymes, broadening cover to include many resistant Gram-negative and anaerobic organisms.

Prescribing in practice

  • Avoid in patients with penicillin allergy, and note co-amoxiclav carries a higher risk of cholestatic jaundice and hepatitis than amoxicillin alone, particularly with prolonged courses.
  • Maternal use around the time of very preterm delivery has been associated with neonatal necrotising enterocolitis, so it is generally avoided for preterm prelabour rupture of membranes.
  • Adjust dosing in significant renal impairment and review the need for continued treatment regularly.

Monitoring

Routine monitoring is not required for short courses, but check liver function with prolonged treatment and review clinical and microbiological response.

Counselling the patient

  • Take with food to reduce stomach upset.
  • Report yellowing of the skin or eyes, dark urine or severe diarrhoea.
  • Complete the prescribed course and seek urgent help for any allergic reaction.

Evidence & guidelines

Co-amoxiclav is a standard broad-spectrum option for mixed infections; its avoidance in preterm prelabour rupture of membranes follows the ORACLE trial findings on neonatal necrotising enterocolitis.

Reference: ORACLE I Trial (Lancet 2001); RCOG Green-top 44 (PPROM 2019); NICE CG190; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs